AI is a game of kings, and OpenAI knows it
Tomas Navratil, Chief Development Officer at Glaukos Corp (NASDAQ:GKOS), sold a total of 5,142 shares of common stock on September 11, 2025. The sales were executed in two transactions at weighted average prices of $87.98 and $88.61, resulting in total proceeds of approximately $453,620. The transactions come as the stock has experienced an 11.9% decline over the past week, with shares now trading at $82.76.
The first transaction involved the sale of 3,194 shares at a weighted average price of $87.98, with prices ranging from $87.43 to $88.43. The second transaction involved the sale of 1,948 shares at a weighted average price of $88.61, with prices ranging from $88.44 to $88.88. For comprehensive insider trading analysis and more insights, InvestingPro subscribers can access detailed financial health metrics and expert research reports.
Following the transactions, Navratil directly owns 75,469 shares of Glaukos Corp, which includes 42,589 restricted stock units that have not yet vested.
The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025.
In other recent news, Glaukos Corporation reported its Q2 2025 earnings, surpassing both earnings per share and revenue forecasts. The company posted an EPS of -$0.24, slightly better than the expected -$0.26, and reported revenue of $124.1 million, exceeding the forecasted $115.52 million. This positive performance was primarily driven by strong U.S. iDose sales, which totaled $31 million, offsetting impacts to other segments due to recent reimbursement changes. Despite these results, Mizuho adjusted its price target for Glaukos from $150 to $130 while maintaining an Outperform rating. The analyst firm cited a mixed outlook for the company as the reason for this adjustment. These developments highlight the company’s ability to exceed financial expectations, even as analysts reassess future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.